Skip to main content

RX Updates

Head-to-Head Study of Upadacitinib vs Abatacept in Patients with RA and Inadequate Response to Biologics: Results from SELECT-CHOICE

Sponsored by AbbVie US Medical Affairs
Your patient with rheumatoid arthritis has not responded to their biologic DMARD – now what? This article highlights the results from SELECT-CHOICE, which is the second head-to-head Phase 3 trial of the JAK inhibitor, upadacitinib, in RA. In this study, upadacitinib was evaluated for noninferiority and superiority assessments vs abatacept, in patients with moderate-to-severe RA who had prior inadequate response to biologic DMARD(s).

BASDAI, ASDAS, ASAS, Oh My! Outcome Measures for Axial Spondyloarthritis

Sponsored by AbbVie US Medical Affairs
Patients with axial spondyloarthritis (axSpA) present with a wide range of symptoms. Given the disease’s heterogeneous presentation, what tools can be used to monitor patients with axSpA and their response to treatment? How can symptoms be tracked and analyzed over time? This article examines some commonly used axSpA disease measures, moving them from esoteric concepts to practical tools for understanding clinical trials and use in everyday practice.

A Closer Look at Psoriatic Arthritis Outcome Measures and Disease Control

Sponsored By AbbVie Medical Affairs
Addressing the heterogeneous manifestations of psoriatic arthritis (PsA) can be challenging for physicians. But how is disease control defined in PsA? What are appropriate treatment targets for use in clinical practice? Join Dr. Alexis Ogdie and Dr. Philip Mease for an overview of composite measures used to assess disease activity and ongoing discussions surrounding disease control and treatment targets for patients with PsA.

Striving for Clinical Remission in Rheumatoid Arthritis

Sponsored By AbbVie Medical Affairs
How do you measure remission in your patients with RA? There are multiple composite measures that can be reliably utilized in clinical practice to assess disease activity and remission. This article highlights these measures and how treatment with upadacitinib, with or without MTX, was assessed across multiple measures of remission in the SELECT program.

Safety Profile of RINVOQ™ (upadacitinib): Analysis of Up to ~3.5 Years of Exposure in Patients With Rheumatoid Arthritis

Sponsored by AbbVie Medical Affairs
Presented here is an update on the longer-term safety profile of upadacitinib, drawing on the integrated analysis of up to ~3.5 years of exposure data from five Phase 3 studies. Dr. Winthrop and Dr. Cush provide additional information from relevant EULAR 2020 posters.

Treatment Switch Between a JAK Inhibitor (upadacitinib) and TNF Inhibitor (adalimumab) in Patients with RA

Sponsored by AbbVie
What happens when a patient doesn’t adequately respond to a JAK inhibitor or a TNF inhibitor? This video reviews data from the SELECT-COMPARE study looking at what happens when RA patients who have an insufficient response to a JAK inhibitor (upadacitinib) or TNF inhibitor (adalimumab) switch to the alternate therapy.

COVID-19 Patient PSA Video Series

Rheumnow Admin
Dr. Jack Cush provides a series of "Patient Safety Advisories" on how patients can cope with the COVID-19 pandemic and rheumatology-related illnesses.

An Overview of Safety Data From the RINVOQ™ (upadacitinib) Phase 3 Program

Rheumnow Admin
Dr. Stanley Cohen presents safety data from both the short-term controlled and long-term portions of the SELECT Phase 3 Program with RINVOQ™.

Achieving Clinical Goals With RINVOQ™ (upadacitinib)

Rheumnow Admin
Dr. Alvin Wells highlights data from the SELECT clinical program and discusses treatment goals in RA.

Key Highlights From the SELECT-COMPARE Trial

Rheumnow Admin
In this video, Dr. Roy Fleischmann discusses data from the SELECT-COMPARE trial with RINVOQ™ (upadacitinib).